Journal article
Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
Abstract
Introduction: Teclistamab (Tec) is the first approved BCMA x CD3 bispecific antibody for the treatment of triple-class-exposed patients with relapsed/refractory multiple myeloma (RRMM) based on the pivotal MajesTEC-1 study. Tec was associated with high overall response rate (ORR) of 63% in heavily pretreated patients. After a longer follow-up of 30.4 months, CR rate was 46.1%, median duration of response (DOR) was 24 months (95% CI, 17.0 - not …
Authors
Tan CR; Asoori S; Nemirovsky D; Derkach A; Brunaldi L; Popat R; Lau C; Kastritis E; Martínez-Lopez J; Bansal R
Journal
Blood, Vol. 144, No. Supplement 1, pp. 5166–5166
Publisher
American Society of Hematology
Publication Date
November 5, 2024
DOI
10.1182/blood-2024-210518
ISSN
0006-4971